He wrote that the he was not aware of any evidence that clinical data were manipulated. Novartis subsidiary AveXis could face a civil or criminal penalty after the US FDA said the Swiss firm manipulated preclinical data for spinal muscular atrophy gene therapy Zolgensma. The agency issued its warning on Friday in response to an investigation by Reuters and other media outlets into whether AstraZeneca had improperly marketed the drug as safe when it was known that patients taking the The Administration said the overall data supported the treatment remaining on the market.
Novartis subsidiary AveXis could face a civil or criminal penalty after the US FDA said the Swiss firm manipulated preclinical data for spinal muscular atrophy gene therapy Zolgensma. The agency issued its warning on Friday in response to an investigation by Reuters and other media outlets into whether AstraZeneca had improperly marketed the drug as safe when it was known that patients taking the The Administration said the overall data supported the treatment remaining on the market.